Morieri, M. L.
Raz, I.
Consoli, A.
Rigato, M.
Lapolla, A.
Broglio, F.
Bonora, E.
Avogaro, A.
Fadini, G. P. http://orcid.org/0000-0002-6510-2097
Ginestra, Federica
Formoso, Gloria
Consoli, Agostino
Andreozzi, Francesco
Sesti, Giorgio
Turco, Salvatore
Lucibelli, Luigi
Gatti, Adriano
Aldigeri, Raffaella
Dei Cas, Alessandra
Felace, Giuseppe
Li Volsi, Patrizia
Sorice, GianPio
Giaccari, Andrea
Mignogna, Carmen
Buzzetti, Raffaella
Filardi, Tiziana
Morano, Susanna
Barchetta, Ilaria
Gisella Cavallo, Maria
Malandrucco, Ilaria
Frontoni, Simona
Carletti, Silvia
D’Angelo, Paola
Leto, Gaetano
Leonetti, Frida
Silvia Morpurgo, Paola
Fiorina, Paolo
Palmieri, Eva
Orsi, Emanuela
Mantovani, Enzo
Franzetti, Ivano
Querci, Fabrizio
Bossi, Antonio
Turchi, Federica
Manfrini, Silvana
Guida, Danila
Placentino, Giuseppe
Beccuti, Guglielmo
Broglio, Fabio
Cavalot, Franco
Nuzzo, Alessandro
Aimaretti, Gianluca
Lamacchia, Olga
Cignarelli, Angelo
Laviola, Luigi
Giorgino, Francesco
Devangelio, Eleonora
Cazzetta, Giuliana
Chianetta, Roberta
Citarrella, Roberto
Tumminia, Andrea
Frittitta, Lucia
Anzaldi, Massimiliano
Buscema, Massimo
Piro, Salvatore
Di Pino, Antonino
Purrello, Francesco
Di Benedetto, Antonino
Russo, Giuseppina
Anichini, Roberto
Solini, Anna
Garofolo, Monia
Del Prato, Stefano
Fattor, Bruno
Paolo Fadini, Gian
Avogaro, Angelo
Lapolla, Annunziata
Sartore, Giovanni
D’Ambrosio, Michele
Da Tos, Virgilio
Frison, Vera
Simioni, Natalino
Cigolini, Massimo
Bonora, Enzo
Brun, Elisabetta
Strazzabosco, Marco
Poli, Maurizio
Rigato, Mauro
Paccagnella, Agostino
Vinci, Carmela
,
Funding for this research was provided by:
Italian Diabetes Society
Università degli Studi di Padova
Article History
Received: 4 November 2022
Accepted: 29 December 2022
First Online: 9 January 2023
Declarations
:
: MLM received lecture fees or advisory board fees from Eli Lilly, MSD, Novo Nordisk, SLAPharma, and Servier. IR Advisory Board: AstraZeneca, Eli Lilly and Company, Novo Nordisk Consultant: AstraZeneca, Curolife, BOL Pharma Speaker’s Bureau: AstraZeneca, Eli Lilly and Company, Novo Nordisk. AC has consulting relationships with Astra Zeneca and Novo Nordisk; has participated in advisory panels for Abbot, Astra Zeneca, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, Mundipharma, Novo-Nordisk, Sanofi-Aventis, Takeda; has received speaker fees from Abbot, Astra Zeneca, Boehringer Ingelheim, Bruno Farmaceutici, Eli Lilly, Merck Sharp & Dohme, Mundipharma, Novo-Nordisk, Sanofi-Aventis, Takeda; has received research supporting grants from Astra Zeneca, Eli Lilly, Novo Nordisk. MR received lecture and advisory board fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Mundipharma, and Novo Nordisk. AL received grant support, lecture or advisory board fees from Novo Nordisk, Sanofi, Abbott, and Eli Lilly. FB was a consultant for Boehringer Ingelheim–Eli Lilly and Company and received lecture fees from Boehringer Ingelheim–Eli Lilly and Company and AstraZeneca. EB received honoraria from Eli Lilly and Company, Novo Nordisk, and Sanofi; travel support from Eli Lilly and Company and Servier Laboratories; and has participated on advisory boards for Abbott, AstraZeneca, Bayer, Becton Dickinson, Boehringer Ingelheim, Daiichi-Sanyo, Eli Lilly and Company, MSD, Novo Nordisk, and Sanofi. AA received research grants, lecture, or advisory board fees from Merck Sharp & Dome, AstraZeneca, Novartis, Boeringher-Ingelheim, Sanofi, Mediolanum, Janssen, Novo Nordisk, Lilly, Servier, and Takeda. GPF received lecture or consultancy fees or grant support from Abbott, AstraZeneca, Boehringer, Lilly, Merck-Sharp-Dome, Mundipharma, Novartis, Novo Nordisk, Sanofi, and Servier.
: The study was conducted in accordance with the principles of the declaration of Helsinki. The protocol was approved by the Ethical Committees of all participating centres.
: In agreement with the National regulations on observational studies, the need for informed consent was waived.